
    
      A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days
      dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate (200mcg
      od) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety using
      an environmental chamber in male subjects with allergic rhinitis
    
  